thalidomide has been researched along with Clinical Deterioration in 1 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
Clinical Deterioration: A critical disease progression, often measured by a set of clinical parameters, which activates HOSPITAL RAPID RESPONSE TEAM.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Although there are several case reports of progressive multifocal leukoencephalopathy (PML) in multiple myeloma (MM), there are few reports of cases associated with pomalidomide." | 7.96 | Pomalidomide-associated progressive multifocal leukoencephalopathy in multiple myeloma: cortical susceptibility-weighted imaging hypointense findings prior to clinical deterioration. ( Ichinohe, T; Ishibashi, H; Kikumto, M; Maruyama, H; Nakamichi, K; Saijo, M; Takahashi, T; Takebayashi, Y; Ueno, H; Umemoto, K; Yasutomi, H, 2020) |
| "Although there are several case reports of progressive multifocal leukoencephalopathy (PML) in multiple myeloma (MM), there are few reports of cases associated with pomalidomide." | 3.96 | Pomalidomide-associated progressive multifocal leukoencephalopathy in multiple myeloma: cortical susceptibility-weighted imaging hypointense findings prior to clinical deterioration. ( Ichinohe, T; Ishibashi, H; Kikumto, M; Maruyama, H; Nakamichi, K; Saijo, M; Takahashi, T; Takebayashi, Y; Ueno, H; Umemoto, K; Yasutomi, H, 2020) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ueno, H | 1 |
| Kikumto, M | 1 |
| Takebayashi, Y | 1 |
| Ishibashi, H | 1 |
| Takahashi, T | 1 |
| Yasutomi, H | 1 |
| Umemoto, K | 1 |
| Nakamichi, K | 1 |
| Saijo, M | 1 |
| Ichinohe, T | 1 |
| Maruyama, H | 1 |
1 other study available for thalidomide and Clinical Deterioration
| Article | Year |
|---|---|
Pomalidomide-associated progressive multifocal leukoencephalopathy in multiple myeloma: cortical susceptibility-weighted imaging hypointense findings prior to clinical deterioration.
Topics: Aged; Clinical Deterioration; Dexamethasone; Female; Humans; Immunologic Factors; JC Virus; Leukoenc | 2020 |